Life Science Ventures Fund II portfolio Company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that preclinical data with its oral T-cell immunotherapy platform, including one preclinical development candidate, VXM10, are being presented at the upcoming “AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications” being held October 26-30, 2017 in Philadelphia, PA, USA. The poster will be presented during Poster Session B in session category “Tumor Immunology Targets” on Sunday October 29, 12:30 PM – 4:00 PM in Hall E.
Sunstone Life Science Fund II portfolion Company CMC Contrast AB acquires Oncoral Pharma Aps to further strengthen its product portfolio within oncology. In connection with the acquisition, the company is re-named to Ascelia Pharma AB.
“Through the acquisition, Ascelia Pharma is truly established as a pioneer in developing novel medicinal products to address unmet medical needs for people living with cancer. The acquisition of Oncoral broadens our oncology product portfolio and fits well with our existing lead drug candidate MangoralTM. With Oncoral, we now have two clinical stage medicinal product candidates in our pipeline and both candidates have the potential to become global leaders in their indications as they will have significant advantages compared to currently available products”, says Magnus Corfitzen, Chief Executive Officer of Ascelia Pharma.
Sunstone Life Science Fund II portfolio company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company’s lead product candidate, VXM01, has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioma, a difficult-to-treat form of brain cancer. Orphan designation is designed to encourage the development of drugs to treat rare diseases and conditions and provides companies with certain incentives, including periods of market exclusivity upon approval, as well as user fee reductions or exemptions. The designation by the European Commission is for the treatment of glioma and by the US FDA for the treatment of malignant glioma.
Sunstone Life Science Fund II portfolio Company Anergis, a company developing proprietary ultra-fast allergy immunotherapy, has announced the top-line results from the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.
A total of 421 patients were randomized at 38 European trial centers in Denmark, Finland, Germany, Lithuania, Norway, Poland, Slovakia and Sweden between September 2016 and January 2017. The trial met its objective to provide conclusive results, with well-balanced treatment groups, very few dropouts, and narrow confidence intervals of the observed treatment effects. The pollen exposure was satisfactory as assessed by the data collected from the pollen traps located close to the trial centers.
Sunstone Life Science Fund III portfolio company, Rigontec GmbH and MSD today announced that MSD will acquire all outstanding shares in Rigontec. Under the terms of the agreement, MSD will make an upfront cash payment of EUR 115 million to Rigontec’s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, MSD may make additional contingent payments of up to EUR 349 million.
Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec’s lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors.
Rigontec was founded in 2014 as a spin-out of the University Bonn, Germany, and has to date raised close to EUR 30 million.